Nothing Special   »   [go: up one dir, main page]

WO1992010172A1 - Solid dosage forms of almokalant and processes for manufacture thereof - Google Patents

Solid dosage forms of almokalant and processes for manufacture thereof Download PDF

Info

Publication number
WO1992010172A1
WO1992010172A1 PCT/SE1991/000815 SE9100815W WO9210172A1 WO 1992010172 A1 WO1992010172 A1 WO 1992010172A1 SE 9100815 W SE9100815 W SE 9100815W WO 9210172 A1 WO9210172 A1 WO 9210172A1
Authority
WO
WIPO (PCT)
Prior art keywords
almokalant
tablets
solid dosage
tablet
dosage form
Prior art date
Application number
PCT/SE1991/000815
Other languages
French (fr)
Inventor
Kjell Andersson
Per Johan Lundberg
Roger Simonsson
Karin Wingstrand
Original Assignee
Aktiebolaget Astra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aktiebolaget Astra filed Critical Aktiebolaget Astra
Priority to JP4500117A priority Critical patent/JPH06503312A/en
Priority to CS931037A priority patent/CZ103793A3/en
Priority to SK55693A priority patent/SK55693A3/en
Publication of WO1992010172A1 publication Critical patent/WO1992010172A1/en
Priority to BG97851A priority patent/BG97851A/en
Priority to NO932052A priority patent/NO932052D0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/795—Polymers containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Definitions

  • This invention relates to solid dosage forms of the antiarrhythmic drug almokalant (p-INN) formulated as immediate release (IR) tablets and extended release (ER) tablets as well as processes for manufacture thereof.
  • p-INN antiarrhythmic drug almokalant
  • the invention relates to the use of the polystyrene sulphonate complex of almokalant in solid dosage forms.
  • Almokalant (p-INN), 4-[3-[ethyl[3-(propylsulfinyl)- propyl]amino]-2-hydroxypropoxy]-benzonitrile free base is a viscous, sticky substance, problematic to handle in the manufacture of solid dosage forms. It has a pronounced tendency to give a repellent odorous degradation product with a smell resembling old onions.
  • the aim of the present invention is to provide solid dosage forms of the antiarrhythmic drug almokalant, formulated as IR-tablets and ER-tablets with improved stability and minimal odour.
  • ER-tablets can be formulated by a variety of formulation principles, such as for instance hydrophilic gel-matrix tablets, matrix tablets, membrane diffusion controlled formulations, osmotic pressure controlled dosage forms etc.
  • formulation principles such as for instance hydrophilic gel-matrix tablets, matrix tablets, membrane diffusion controlled formulations, osmotic pressure controlled dosage forms etc.
  • almokalant polystyrene sulphonate complex (A-PSS) , had a much better stability, less repelling odour and was much easier to handle in tablet manufacture.
  • ER tablets it is necessary to mix the formed complex with e.g. a hydrophilic matrix. It is especially preferable to use hydroxypropyl methylcellulose as the ge forming substance. It is further preferred to use a mixture of HPMC containing both low and high molecular weight HPMC.
  • Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water.
  • a reference preparation was produced by dissolving the free base in a 2M hydrochloric acid solution and using this solution to granulate the excipients.
  • the A-PSS tablet was prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to tablets was performed on a Korsch Pharmapress 100.
  • the reference tablet (Ref. ex. I) was prepared by making a granulating solution of the ingredients 1 and 3. The powders in 2 were mixed and then granulated with the prepared solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets compressed on the same machine.
  • Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water. After drying the granulate was milled and then mixed with the lubricant sodium stearyl fumarate whereupon compression to tablets was done.
  • a reference preparation (Ref. ex. II) was produced by dissolving the free base in an aqueous tartaric acid solution and using this solution to granulate the excipients.
  • Lactose pwd 84.5 Lactose anhydrous Avicel ® PH 101 Polyvidone K-25 3.
  • Water, purified Tartaric acid 4.
  • the A-PSS tablets were prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to tablets were performed on a Korsch Pharmapress 100.
  • the reference tablet (Ref. ex. II) was prepared by making a granulating solution of 1 and 3. The powders 2 were mixed and granulated with the solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets were compressed on the same machine.
  • the odour intensity of the two formulations were compared immediately after manufacturing and after 1 month of storage in glass bottles .
  • Immediate release tablets of almokalant can be prepared in suitable strengths.
  • the A-PSS tablets were prepared by first mixing the ingredients 1. The mixture was granulated with a solution made of ingredients 2. After drying and milling ingredients 3 were admixed, whereupon compression to tablets were performed on a Korsch Pharmapress 100.
  • Disintegration (without discs): 0.6-1.0 min. 0.2-0.4 min.
  • Extended release tablets of almokalant were prepared by mixing A-PSS 95 parts, hydroxypropyl methylcellulose (HPMC) 50 cps 40 parts, HPMC 10000 cps 160 parts and hydroxypropyl cellulose (HPC) 50 parts and then granulating the mixture with ethanol 99.5%. After drying the granulate was milled and then mixed with sodium stearyl fumarate whereupon compression to tablets was done.
  • HPMC hydroxypropyl methylcellulose
  • HPMC 10000 cps 160 parts HPMC 10000 cps 160 parts
  • HPPC hydroxypropyl cellulose
  • a reference preparation (Ref. ex. Ill) was made by dissolving the free base in ethanol (99.5%) and using this solution to granulate the dry excipients, and otherwise following the same way of production.
  • HPMC 50 cps (Metolose ® 60SH50) 40.0 40.0 3 .
  • HPMC 10000 cps (Methocel ® ⁇ E10MCR) 4.
  • H HPPCC LLFF (KKlluuccee:l ® LF) 5. Ethanol 99. 5% 6.
  • Sodium stearyl fumarate (Pruv ®*)
  • Tablets made using the free base have inferior binding properties.
  • the release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle, 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
  • Extended release tablets of almokalant can be prepared in suitable strengths and with different release rates.
  • Lactose pwd HPMC 50 cps (Metolose ® 60SH50)
  • HPMC lOOOOcps (Methocel ® E10MCR)
  • HPC LF (Klucel ® LF)
  • Polyethylene glycol 20M (Carbowax ® 20M) 30.0
  • Polyethylene glycol 6000 (Carbowax ® 6000) 42.0
  • Compression to tablets was performed on a Korsch Pharmapress 100.
  • the tablet machine was equipped with compression force registration.
  • the release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
  • Controlled release tablets were prepared by granulating 54.3 parts active substance, 30.0 parts mannitol, 154 parts HPMC 50 cps, 221 parts HPMC 10,000 cps, 37.5 parts HPC, 0.3 parts propyl gallate with a solution of 45 parts PEG 20,000 (Ex. 6) or PVP K-25 (Ex. 7) dissolved in 105 parts of water.
  • the dried granulate was lubricated with 2.7 parts of sodium stearyl fumarate.
  • HPMC Methodolose ® 60SH50
  • HPMC Methodoel ® E10MCR
  • Tablet weight 545 mg 545 mg compression force (kN) : tablet hardness (kP):
  • the release rate was determined in USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
  • almokalant free base in pharmaceutical formulation apart from the inconvenience of handling a sticky, viscous substance - results in dosage forms with inferior stability and palatability as well as in inferior technical properties.
  • almokalant polystyrene sulphonate complex in pharmaceutical formulation eases the handling and results in more stabile and more palatable dosage forms.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Chemical Treatment Of Metals (AREA)

Abstract

Solid oral pharmaceutical dosage forms containing a complex of almokalant as well as processes for their manufacture.

Description

SOLID DOSAGE FORMS OF ALMOKALANT AND PROCESSES FOR MANUFACTURE THEREOF
Field of the invention
This invention relates to solid dosage forms of the antiarrhythmic drug almokalant (p-INN) formulated as immediate release (IR) tablets and extended release (ER) tablets as well as processes for manufacture thereof.
Specifically the invention relates to the use of the polystyrene sulphonate complex of almokalant in solid dosage forms.
Background of the invention
No solid dosage forms containing the polystyrene sulphonate complex of almokalant have been reported. The polystyrene sulphonate complex of almokalant is described in the European patent application EP 90850242.0 (our ref. H 1020-1), which is not publically available at the time of filing the basic application in Sweden, but will be so shortly thereafter.
Almokalant (p-INN), 4-[3-[ethyl[3-(propylsulfinyl)- propyl]amino]-2-hydroxypropoxy]-benzonitrile free base is a viscous, sticky substance, problematic to handle in the manufacture of solid dosage forms. It has a pronounced tendency to give a repellent odorous degradation product with a smell resembling old onions.
Several different ways were tested in order to prepare a solid dosage form of almokalant. Commonly used methods had the following disadvantages.
Due to the instability of the base and its tendency to worsen tablet binding properties, solid dosage forms of the free base are difficult to produce. See further reference example III.-
Tablets prepared by conventional technique, with almokalant dissolved in an acidic granulating solution, have inferior stability properties and develop a repelling onion-like odour. See further reference examples I and III.
The use of complexes of drug substances with ion exchange resins in pharmaceutical formulation is described previously. A way to obtain a controlled release suspension containing codeine is described by Amsel L.P. et al "Unique Oral Controlled Release Systems": In-Vivo Drug Release Pattern pp 83-93 where a complex between codeine and an ion exchange resin is coated with a diffusion membrane and then formulated into a suspension. In addition, Pennwalt Corporation has published a series of patents describing the use of ion exchange resins having pharmacologically active substances absorbed thereon for use in controlled release preparations either as such or further coated with diffusion membranes (US Pat 4,221,778, EP 0171 528, EP 0 254 811). Other uses of ion exchange resin complexes with drugs in pharmaceutical formulation is for example summarized by Raghunathan et al. J Pharm Sci 1981, 70, (No 4), 379-384.
Description of the invention
The aim of the present invention is to provide solid dosage forms of the antiarrhythmic drug almokalant, formulated as IR-tablets and ER-tablets with improved stability and minimal odour. ER-tablets can be formulated by a variety of formulation principles, such as for instance hydrophilic gel-matrix tablets, matrix tablets, membrane diffusion controlled formulations, osmotic pressure controlled dosage forms etc. As the use of solid substances in tablet manufacture in general is advantageous and facilitates the production different ways to prepare solid dosage forms were investigated.
As it had been noticed that the compound almokalant as such in acidic solutions has a good stability, which make it possible to autoclave it without noteworthy degradation, the addition of acid compounds were tested.
Although complex-binding to ion-exchange resins of viscous, unstable, pharmacologically active agents, to form a stabile solid complex suitable for pharmaceutical processing has not been previously described, this was tested with almokalant.
Thus, it was tested to use the polystyrene sulfonate complex of almokalant in the formulation of pharmaceutica dosage forms. It was then unexpectedly found that almokalant polystyrene sulphonate complex (A-PSS) , had a much better stability, less repelling odour and was much easier to handle in tablet manufacture.
To form ER tablets it is necessary to mix the formed complex with e.g. a hydrophilic matrix. It is especially preferable to use hydroxypropyl methylcellulose as the ge forming substance. It is further preferred to use a mixture of HPMC containing both low and high molecular weight HPMC.
The use of different mixtures of HPMC gives according to known technics (Journal of Controlled release, 5 (1987) 159-172), different release rates of the active ingredien almokalant. EXAMPLES
Example 1
Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water.
After drying the granulate was milled and then mixed with sodium stearyl fumarate and compressed to tablets.
A reference preparation was produced by dissolving the free base in a 2M hydrochloric acid solution and using this solution to granulate the excipients.
A-PSS tablet Ref. Ex 1 Ex I
1. A-PSS corresp. to almokalant 50.0
Almokalant - 50.0
2. Lactose pwd 84.5 Lactose anhydrous Avicel® PH 101 Povidone® K-25
Polyvinyl pyrrolidone, cross-linked Aerosil
3. Water, purified Hydrochloric acid 2M (corresp. to HC1)
4. Sodium stearyl fumarate Magnesium stearate Talcum Polyvinyl pyrrolidone, cross-linked
Figure imgf000006_0001
The A-PSS tablet was prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to tablets was performed on a Korsch Pharmapress 100.
The reference tablet (Ref. ex. I) was prepared by making a granulating solution of the ingredients 1 and 3. The powders in 2 were mixed and then granulated with the prepared solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets compressed on the same machine.
Punches: Tablet weight: Hardness: Disintegration:
Figure imgf000007_0001
Stability data of storage in glass bottles. Degradation measured as area sum of byproducts in a HPLC-system
0.81 2.11 0.88 2.83
Figure imgf000007_0002
1.82 3.41
3.5 months in 25°C 0.88 2.87
Example 2
Immediate release tablets of almokalant were prepared by mixing A-PSS 90 parts, lactose 85 parts, microcrystalline cellulose 91 parts and polyvinyl pyrrolidone 27 parts and then granulating the mixture with purified water. After drying the granulate was milled and then mixed with the lubricant sodium stearyl fumarate whereupon compression to tablets was done. A reference preparation (Ref. ex. II) was produced by dissolving the free base in an aqueous tartaric acid solution and using this solution to granulate the excipients.
A-PSS tablet Ref. tablet Ex 2 Ex II
1. A-PSS corresp. to almokalant 50.0 Almokalant 50.0
2. Lactose pwd 84.5 Lactose anhydrous Avicel® PH 101 Polyvidone K-25 3. Water, purified Tartaric acid 4. Sodium stearyl fumarate Talcum Polyvinyl pyrrolidone, cross-linked
Punches: Tablet weight: Hardness: Disintegration:
Figure imgf000008_0001
The A-PSS tablets were prepared by first mixing ingredients 1 and 2. The mixture was granulated with 3. After drying and milling 4 was admixed, whereupon compression to tablets were performed on a Korsch Pharmapress 100.
The reference tablet (Ref. ex. II) was prepared by making a granulating solution of 1 and 3. The powders 2 were mixed and granulated with the solution. After drying and milling the lubricant, glidant and disintegrant in 4 were admixed and tablets were compressed on the same machine.
The odour intensity of the two formulations were compared immediately after manufacturing and after 1 month of storage in glass bottles .
Odour intensity
A-PSS tablets Ref. Ex. 2 Ex. II
Freshly prepared + ++
(some smell, but (pronounced smell not of onions. ) of onions. )
1 month +++
(some smell, but (strong smell of not of onions. ) of onions)
Example 3
Immediate release tablets of almokalant can be prepared in suitable strengths.
In Ex. 1 and 2 a 50 rag preparation was described. Below are examples of 70 mg and 1.8 mg preparations shown.
Figure imgf000009_0001
The A-PSS tablets were prepared by first mixing the ingredients 1. The mixture was granulated with a solution made of ingredients 2. After drying and milling ingredients 3 were admixed, whereupon compression to tablets were performed on a Korsch Pharmapress 100.
Punches: 10 mm 5.5x10.5 mm
Tablet weight: 322 mg 150 mg Hardness: 9-10 kP 9-10 kP
Disintegration (without discs): 0.6-1.0 min. 0.2-0.4 min.
Example 4
Extended release tablets of almokalant were prepared by mixing A-PSS 95 parts, hydroxypropyl methylcellulose (HPMC) 50 cps 40 parts, HPMC 10000 cps 160 parts and hydroxypropyl cellulose (HPC) 50 parts and then granulating the mixture with ethanol 99.5%. After drying the granulate was milled and then mixed with sodium stearyl fumarate whereupon compression to tablets was done.
A reference preparation (Ref. ex. Ill) was made by dissolving the free base in ethanol (99.5%) and using this solution to granulate the dry excipients, and otherwise following the same way of production.
Example 4 Ref.ex. Ill
Ingredient mg/tablet mg/tablet
1. A-PSS corresp. to almokalant 50.0 Almokalant 50.0
2. HPMC 50 cps (Metolose® 60SH50) 40.0 40.0 3 . HPMC 10000 cps (Methocel ®^ E10MCR) 4. H HPPCC LLFF ((KKlluuccee:l® LF) 5. Ethanol 99. 5% 6. Sodium stearyl fumarate (Pruv ®*)
Figure imgf000011_0001
Ingredients 1 to 4 were mixed. The mixture was granulated with ethanol. After drying and milling the granulate was mixed with 6.
Compression to tablets was performed on a Korsch
Pharmapress 100 with 11 mm circular punches. The tablet machine was equipped with compression force registration.
Figure imgf000011_0002
Tablets made using the free base have inferior binding properties.
Odour intensit
Freshly prepared
Figure imgf000011_0003
The release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle, 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
Figure imgf000012_0001
Example 5
Extended release tablets of almokalant can be prepared in suitable strengths and with different release rates.
In Ex. 4 a preparation with 50 mg strength is described. Below follows examples of 10 mg and 100 mg.
10 mg 100 mg Ex. 5a Ex. 5b
Ingredient mg/tablet
1. A-PSS corresp. to almokalant
2. Lactose pwd HPMC 50 cps (Metolose® 60SH50)
HPMC lOOOOcps (Methocel® E10MCR) HPC LF (Klucel® LF)
Figure imgf000012_0002
3. Polyethylene glycol 20M (Carbowax® 20M) 30.0 Polyethylene glycol 6000 (Carbowax® 6000) 42.0
4. Water, purified 70.0 98.1
5. Sodium stearyl fumarate (Pruv ) 1.6 2.3 1 and 2 were mixed. The mixture was granulated with a solution made of 3 and 4. After drying and milling the granulate was mixed with 5.
Compression to tablets was performed on a Korsch Pharmapress 100. The tablet machine was equipped with compression force registration.
Figure imgf000013_0001
The release rate was determined from 6 individual tablets using USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
10 mg ER tablet 100 mg ER tablet
Ex. 5a Ex. 5b cumulative cumulative hours % released % released average (min-max) average (min-max)
2 27 (27-28) 17 (17-18)
4 44 (43-45) 28 (26-29)
6 37 (35-39)
8 72 (70-75)
10 55 (52-60)
12 105 (96-109)
20 91 (84-95)
24 100(99-101) Examples 6-7
Controlled release tablets were prepared by granulating 54.3 parts active substance, 30.0 parts mannitol, 154 parts HPMC 50 cps, 221 parts HPMC 10,000 cps, 37.5 parts HPC, 0.3 parts propyl gallate with a solution of 45 parts PEG 20,000 (Ex. 6) or PVP K-25 (Ex. 7) dissolved in 105 parts of water. The dried granulate was lubricated with 2.7 parts of sodium stearyl fumarate.
Example 6 Example 7
Ingredient mg/tablet
1. A-PSS corresp. to almokalant
2. Mannitol pwd
3. HPMC (Metolose® 60SH50) 4. HPMC (Methocel® E10MCR)
5. HPC (Klucel® LF)
6. Propyl gallate
7. PEG (Carbowax® 20M) PVP (Povidone® K-25) 8. Water
9. Sodium stearyl fumarate (Pruv )
Figure imgf000014_0001
Ingredients 1 to 6 were mixed. The mixture was granulated with a solution made of 7 and 8. After drying the granulate was mixed with 9.
Compression to tablets were performed on a Korsch Pharmapress 100 with 11 mm circular punches. The tablet machine was equipped with compression force registration .
Example 6 Example 7
Tablet weight: 545 mg 545 mg compression force (kN) : tablet hardness (kP):
Figure imgf000015_0001
The release rate was determined in USP dissolution apparatus 2 with the paddle rotating at 100 r/min and the tablet placed in a stationary basket above the paddle. 500 ml buffer solution pH 6.8 kept at 37°C was used as dissolution medium.
Cumulative % released Average (min-max)
Example 6 Example 7
2h 17(17-18) 18(17-18)
4h 28(28-29) 28(28-29)
6h 38(38-39) 38(37-39) lOh 55(54-56) 54(53-56)
16h 74(73-76) 73(71-74)
The examples show that PEG 20000 and PVP K-25 both function in the process.
Discussion
From the examples it is quite obvious that the use of almokalant free base in pharmaceutical formulation - apart from the inconvenience of handling a sticky, viscous substance - results in dosage forms with inferior stability and palatability as well as in inferior technical properties. The use of almokalant polystyrene sulphonate complex in pharmaceutical formulation eases the handling and results in more stabile and more palatable dosage forms.
The best mode of carrying out the invention known at present is to prepare the formulation according to Examples 6-7.

Claims

Claims
1. A pharmaceutical dosage form of almokalant wherein said almokalant in the form of a complex with polystyrene sulphonate optionally mixed with pharmaceutical excipients forms an oral solid dosage form.
2. A dosage form according to claim 1 wherein the pharmaceutical excipients contain a hydrophilic matrix.
3. A dosage form according to claim 2 wherein the hydrophilic matrix is hydroxypropyl methylcellulose.
4. A dosage form according to claim 3 wherein the hydroxypropyl methylcellulose contains both low and high molecular weight hydroxypropyl methylcellulose.
5. A process for the manufacture of a solid dosage form according to claim 1 wherein a) almokalant is reacted with polystyrene sulphonic acid to form a complex b) the complex is mixed with pharmaceutical excipients and an oral solid dosage form is prepared according to any known method.
6. A process according to claim 5, wherein the pharmaceutical excipients contain a hydrophilic matrix.
7. A process according to claim 6, wherein the hydrophilic matrix is hydroxypropyl methylcellulose.
PCT/SE1991/000815 1990-12-07 1991-12-03 Solid dosage forms of almokalant and processes for manufacture thereof WO1992010172A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP4500117A JPH06503312A (en) 1990-12-07 1991-12-03 Solid dosage form of almocurant and method for its preparation
CS931037A CZ103793A3 (en) 1990-12-07 1991-12-03 Solid dosing forms of almocalant, and process for preparing thereof
SK55693A SK55693A3 (en) 1990-12-07 1991-12-03 Solid dosage forms of almokalant and processes for manufacture thereof
BG97851A BG97851A (en) 1990-12-07 1993-06-04 Hard dosed forms of almocalante and method for obtaining them
NO932052A NO932052D0 (en) 1990-12-07 1993-06-04 FIXED DOSAGE FORMS OF ALMOCALANT AND PROCEDURES PREPARING THEREOF

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9003902-5 1990-12-07
SE9003902A SE9003902D0 (en) 1990-12-07 1990-12-07 SOLID DOSAGE FORMS OF A DRUG

Publications (1)

Publication Number Publication Date
WO1992010172A1 true WO1992010172A1 (en) 1992-06-25

Family

ID=20381121

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/SE1991/000815 WO1992010172A1 (en) 1990-12-07 1991-12-03 Solid dosage forms of almokalant and processes for manufacture thereof

Country Status (26)

Country Link
EP (1) EP0560821A1 (en)
JP (1) JPH06503312A (en)
CN (1) CN1063039A (en)
AP (1) AP258A (en)
AU (1) AU8930791A (en)
BG (1) BG97851A (en)
CA (1) CA2097178A1 (en)
CZ (1) CZ103793A3 (en)
FI (1) FI932554A (en)
HU (1) HUT64217A (en)
IE (1) IE914137A1 (en)
IL (1) IL100150A0 (en)
IS (1) IS3788A7 (en)
LT (1) LTIP1717A (en)
MA (1) MA22355A1 (en)
MX (1) MX9102325A (en)
MY (1) MY106776A (en)
NZ (1) NZ240731A (en)
PT (1) PT99719A (en)
SE (1) SE9003902D0 (en)
SK (1) SK55693A3 (en)
TN (1) TNSN91117A1 (en)
TW (1) TW215057B (en)
WO (1) WO1992010172A1 (en)
YU (1) YU186891A (en)
ZA (1) ZA919264B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026867A2 (en) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Solid instant-release forms of administration and process for producing the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9611328D0 (en) * 1996-05-31 1996-08-07 Zeneca Ltd Pharmaceutical compositions
US6024981A (en) * 1997-04-16 2000-02-15 Cima Labs Inc. Rapidly dissolving robust dosage form
JP4504467B2 (en) * 1998-07-30 2010-07-14 佐藤製薬株式会社 Orally disintegrating tablets
JP7426685B2 (en) * 2018-06-14 2024-02-02 株式会社東洋新薬 tablet

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218333A (en) * 1988-05-11 1989-11-15 Glaxo Group Ltd Ranitidine adsorbates
EP0404747A1 (en) * 1989-06-20 1990-12-27 Aktiebolaget Hässle Novel polystyrenesulfonate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE8705150D0 (en) * 1987-12-23 1987-12-23 Haessle Ab NOVEL ANTIARRHYTHMIC AGENTS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2218333A (en) * 1988-05-11 1989-11-15 Glaxo Group Ltd Ranitidine adsorbates
EP0404747A1 (en) * 1989-06-20 1990-12-27 Aktiebolaget Hässle Novel polystyrenesulfonate

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026867A2 (en) * 1996-01-26 1997-07-31 Boehringer Mannheim Gmbh Solid instant-release forms of administration and process for producing the same
WO1997026867A3 (en) * 1996-01-26 1997-09-25 Boehringer Mannheim Gmbh Solid instant-release forms of administration and process for producing the same
US6521262B2 (en) 1996-01-26 2003-02-18 Heidelberg Pharma Holding Gmbh Solid instant-release forms of administration and process for producing the same
CZ298897B6 (en) * 1996-01-26 2008-03-05 Heidelberg Pharma Holding Gmbh Solid instant-release form of administration, process for preparing such form of administration and use of therapeutic active substances when preparing such solid instant-release form of administration

Also Published As

Publication number Publication date
BG97851A (en) 1994-04-29
SE9003902D0 (en) 1990-12-07
CN1063039A (en) 1992-07-29
IS3788A7 (en) 1992-06-08
MX9102325A (en) 1992-06-01
YU186891A (en) 1994-04-05
TW215057B (en) 1993-10-21
FI932554A0 (en) 1993-06-04
NZ240731A (en) 1993-10-26
JPH06503312A (en) 1994-04-14
SK55693A3 (en) 1993-10-06
IL100150A0 (en) 1992-08-18
LTIP1717A (en) 1995-07-25
AU8930791A (en) 1992-07-08
PT99719A (en) 1992-10-30
CZ103793A3 (en) 1994-02-16
HU9301670D0 (en) 1993-09-28
CA2097178A1 (en) 1992-06-08
EP0560821A1 (en) 1993-09-22
TNSN91117A1 (en) 1992-10-25
FI932554A (en) 1993-06-08
MY106776A (en) 1995-07-31
ZA919264B (en) 1992-08-26
IE914137A1 (en) 1992-06-17
HUT64217A (en) 1993-12-28
AP258A (en) 1993-06-03
MA22355A1 (en) 1992-07-01
AP9100338A0 (en) 1992-01-31

Similar Documents

Publication Publication Date Title
US6350471B1 (en) Tablet comprising a delayed release coating
US7749536B2 (en) Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
WO2003055475A1 (en) Controlled release pharmaceutical formulation containing venlafaxine
SK175997A3 (en) Controlled release formulations for poorly soluble drugs
KR101120729B1 (en) Controlled-release compositions
US20030118647A1 (en) Extended release tablet of metformin
NO341321B1 (en) Preparation for oral administration of tamsulosin hydrochloride and controlled release formulation granule comprising the same
EP1239837A2 (en) Direct compression polymer tablet core
RU2300368C2 (en) Ibuprofen-containing composition
JP2005532289A (en) Sustained release pharmaceutical preparation and method for producing the same
JP5124286B2 (en) Sustained release preparation and method for producing the same
US5149523A (en) Polystyrenesulfonate-drug complex and solid dosage forms thereof
AP258A (en) Solid dosage forms of almokalant and processes for manufacture thereof.
EP1818048A1 (en) Pharmaceutical formulations of aliphatic amine polymers and methods for their manufacture
EP0266707B1 (en) Sustained release labetalol tablet
US4940580A (en) Sustained release labetalol tablets
EP1079834B1 (en) Stable compositions comprising levosimendan and alginic acid
CA2532714C (en) Oral sustained-release tablet comprising 4-(2-methyl-1-imidazolyl)-2,2-diphenylbutylamide
JP2680602B2 (en) Sustained-release tablets
CA2576135C (en) Direct compression polymer tablet core
US20060177501A1 (en) Film Coated Tablets Containing Ibuprofen
RU98111607A (en) PHARMACEUTICAL FINISHED FORMS

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR CA CH CS DE DK ES FI GB HU JP KP KR LK LU MG MW NL NO PL RO SD SE SU

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GN GR IT LU MC ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2097178

Country of ref document: CA

Ref document number: 93-00737

Country of ref document: RO

WWE Wipo information: entry into national phase

Ref document number: 1991920708

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 55693

Country of ref document: SK

Ref document number: PV1993-1037

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 932554

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1991920708

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV1993-1037

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: PV1993-1037

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1991920708

Country of ref document: EP